Ferroptosis and the Thyroid: Emerging Links Between Iron Homeostasis, Oxidative Stress, and Thyroid Disease
- 1Metabolic Center for Wellness, P.A., Oviedo, FL 32765, USA
Abstract
Ferroptosis is a regulated form of cell death characterized by iron-dependent phospholipid peroxidation and failure of cellular antioxidant defenses. Although increasingly implicated in cancer and other chronic diseases, its role in thyroid physiology and thyroid disease remains incompletely defined. The thyroid gland represents a particularly relevant setting in which to examine ferroptosis because normal thyroid hormone synthesis requires iron-dependent enzymatic activity and controlled reactive oxygen species generation while simultaneously relying on robust antioxidant systems to protect follicular cells from oxidative injury. This review examines the intersection of iron homeostasis, redox regulation, lipid peroxidation, and ferroptosis across the spectrum of thyroid disease. Current evidence suggests substantial differences among disease states. Thyroid malignancy has generated the strongest mechanistic and preclinical evidence for ferroptosis-related pathways, including alterations in glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), acyl-CoA synthetase long-chain family member 4 (ACSL4), and other regulators of ferroptotic susceptibility. In Hashimoto’s thyroiditis, initial direct evidence has begun to emerge, including reduced GPX4 and increased lipid peroxidation in patient thyroid tissue together with cytokine-induced, ferrostatin-reversible thyrocyte death in vitro, whereas in Graves’ disease and benign thyroid nodular disease the evidence remains largely inferential. Current orbital-tissue data further suggest that fibroblasts in thyroid-associated ophthalmopathy may resist, rather than undergo, ferroptosis. Oxidative stress, mitochondrial dysfunction, inflammation, and impaired antioxidant defenses provide biologic plausibility across these conditions but do not by themselves establish ferroptotic cell death. Importantly, oxidative stress and lipid peroxidation alone should not be considered synonymous with ferroptosis. Clarifying the role of ferroptosis in thyroid disease will require thyroid-specific mechanistic studies, validated biomarkers, and translational investigation. Improved understanding of these pathways may ultimately reveal disease-specific opportunities to protect vulnerable thyroid cells in benign disease while exploiting ferroptotic susceptibility therapeutically in thyroid malignancy.
Related
- ERK5 Signaling and Ferroptosis in Bone Homeostasis: Emerging Connections and Therapeutic Perspectives
- Mitochondrial Copper Homeostasis in Diabetic Kidney Disease: Emerging Links Between Metabolic Stress, Respiratory Chain Dysfunction, and Renal Injury.
- METTL7B-Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression.
- Stress-induced vtRNA1-1 modulates redox homeostasis and ferroptosis susceptibility in hepatocellular carcinoma cells.
- Cooperative inhibition of mTORC1 disrupts iron–redox homeostasis and triggers ferritinophagy-dependent ferroptosis in hepatocellular carcinoma
BibTeX
@article{mazza2026ferroptosis,
title = {{Ferroptosis and the Thyroid: Emerging Links Between Iron Homeostasis, Oxidative Stress, and Thyroid Disease}},
author = {Angela D. Mazza},
journal = {Metabolites},
year = {2026},
month = nov,
doi = {10.3390/metabo16110850},
url = {https://www.mdpi.com/2218-1989/16/11/850},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ferroptosis and the Thyroid: Emerging Links Between Iron Homeostasis, Oxidative Stress, and Thyroid Disease
AU - Angela D. Mazza
PY - 2026
DA - 2026/11/04
JO - Metabolites
DO - 10.3390/metabo16110850
UR - https://www.mdpi.com/2218-1989/16/11/850
AB - Ferroptosis is a regulated form of cell death characterized by iron-dependent phospholipid peroxidation and failure of cellular antioxidant defenses. Although increasingly implicated in cancer and other chronic diseases, its role in thyroid physiology and thyroid disease remains incompletely defined. The thyroid gland represents a particularly relevant setting in which to examine ferroptosis because normal thyroid hormone synthesis requires iron-dependent enzymatic activity and controlled reactive oxygen species generation while simultaneously relying on robust antioxidant systems to protect follicular cells from oxidative injury. This review examines the intersection of iron homeostasis, redox regulation, lipid peroxidation, and ferroptosis across the spectrum of thyroid disease. Current evidence suggests substantial differences among disease states. Thyroid malignancy has generated the strongest mechanistic and preclinical evidence for ferroptosis-related pathways, including alterations in glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), acyl-CoA synthetase long-chain family member 4 (ACSL4), and other regulators of ferroptotic susceptibility. In Hashimoto’s thyroiditis, initial direct evidence has begun to emerge, including reduced GPX4 and increased lipid peroxidation in patient thyroid tissue together with cytokine-induced, ferrostatin-reversible thyrocyte death in vitro, whereas in Graves’ disease and benign thyroid nodular disease the evidence remains largely inferential. Current orbital-tissue data further suggest that fibroblasts in thyroid-associated ophthalmopathy may resist, rather than undergo, ferroptosis. Oxidative stress, mitochondrial dysfunction, inflammation, and impaired antioxidant defenses provide biologic plausibility across these conditions but do not by themselves establish ferroptotic cell death. Importantly, oxidative stress and lipid peroxidation alone should not be considered synonymous with ferroptosis. Clarifying the role of ferroptosis in thyroid disease will require thyroid-specific mechanistic studies, validated biomarkers, and translational investigation. Improved understanding of these pathways may ultimately reveal disease-specific opportunities to protect vulnerable thyroid cells in benign disease while exploiting ferroptotic susceptibility therapeutically in thyroid malignancy.
SN - 2218-1989
ER -